The NIH rejected a petition urging the agency to use a controversial provision of federal law to widen access to a cancer drug by forcing the manufacturers to license their…

A top FDA official says the agency needs to start using accelerated approval to advance gene therapies for rare diseases.

Voter registration on HealthCare.gov should be available when Americans begin applying for health insurance this fall, ahead of Election Day 2024.

With biosecurity at the forefront of people’s minds, this is an opportune moment to think differently.

Makers of flu vaccines say they could manufacture hundreds of millions of bird flu shots for humans within months if a new strain jumps the species divide.

FDA Commissioner Robert Califf wants private insurers to chip in on doing post-approval clinical research on drugs.

The federal judge who could upend access to an abortion medication pressed government lawyers in a hearing about the safety and approval process for the drug.

Under mounting pressure, Novo Nordisk plans to cut U.S. list prices for several insulin products by up to 75%, the latest big drugmaker to take such a step.

The Biogen senior executive who supervised the development and controversial approval of the Alzheimer’s treatment Aduhelm left the company last week.

New legislation introduced by Sen. Bernie Sanders would prohibit all insulin manufacturers from charging more than $20 per vial.

An experimental Eli Lilly drug failed to prevent memory loss in a study of healthy older people with a high risk of developing clinical Alzheimer’s disease.

FDA Commissioner Robert Califf would like to get rid of voting at the end of advisory committee meetings "as much as possible."

The White House will propose expanding authority to negotiate what Medicare pays for more drugs than the limited number approved last year.

It has been more than 11 years since Julia Young was diagnosed with advanced ovarian cancer, and two years since it spread to her lymph system. By her own account,…

Walgreens won't dispense abortion pills in several states where they remain legal amid threats from state officials and pressure from anti-abortion activists.

Lilly's slashing of prices for some of its insulin products raised questions about what will happen to other efforts to provide low-cost insulin.

A FDA advisory panel backed a GSK respiratory syncytial virus vaccine, setting it up for a race with Pfizer to have the first approved U.S. shot against RSV.

House Republicans have launched an investigation into PBMs, dialing up the scrutiny of the middlemen who play an important role in how much medicines cost.

Pfizer is in talks to acquire Seagen, the latest potential deal for a big drug company aimed at adding a promising class of targeted cancer therapies.

Moderna has paid $400 million to the U.S. government for the rights to a chemical technique used in its successful Covid-19 vaccines.

A court challenge to approval of mifepristone could set a sweeping precedent that might undermine the infrastructure for evaluating all drugs.

Some doctors recommend that women who are done with childbearing, and undergoing other pelvic surgeries, have their tubes removed.

Cystic fibrosis patients and their families are getting caught in the middle of a struggle between Vertex and insurers over copays.

Pfizer discontinued a significant percentage of participants in a study testing a Lyme vaccine due to violations at trial sites run by a third party.

Over four decades, GSK chose to keep quiet on the cancer risks of the recalled heartburn medication Zantac.

The biotech industry is in shake-out mode after the ranks of public drug developers swelled in recent years amid an IPO boom.

Sanofi says its global head of research and development, John Reed, is stepping down after shareholders criticized its development pipeline.

A German union opposes splitting up Bayer after the departure of its chief executive and warned the company should not bow to pressure from hedge fund activism.

A new class of treatments for Covid-19 variants could help restock the country’s armory but faces an uncertain road to the commercial market.

In a bid to expand access to pricey cystic fibrosis treatments, a coalition of families and activists is petitioning four governments to make it possible to obtain generic versions of…